56 related articles for article (PubMed ID: 33098134)
21. Global incidence trends in primary liver cancer by age at diagnosis, sex, region, and etiology, 1990-2017.
Liu Z; Suo C; Mao X; Jiang Y; Jin L; Zhang T; Chen X
Cancer; 2020 May; 126(10):2267-2278. PubMed ID: 32201944
[TBL] [Abstract][Full Text] [Related]
22. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
[TBL] [Abstract][Full Text] [Related]
23. Pathologic complete response to chemoembolization improves survival outcomes after curative surgery for hepatocellular carcinoma: predictive factors of response.
Yang K; Sung PS; You YK; Kim DG; Oh JS; Chun HJ; Jang JW; Bae SH; Choi JY; Yoon SK
HPB (Oxford); 2019 Dec; 21(12):1718-1726. PubMed ID: 31171489
[TBL] [Abstract][Full Text] [Related]
24. Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium.
DiNorcia J; Florman SS; Haydel B; Tabrizian P; Ruiz RM; Klintmalm GB; Senguttuvan S; Lee DD; Taner CB; Verna EC; Halazun KJ; Hoteit M; Levine MH; Chapman WC; Vachharajani N; Aucejo F; Nguyen MH; Melcher ML; Tevar AD; Humar A; Mobley C; Ghobrial M; Nydam TL; Amundsen B; Markmann JF; Berumen J; Hemming AW; Langnas AN; Carney CA; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
Ann Surg; 2020 Apr; 271(4):616-624. PubMed ID: 30870180
[TBL] [Abstract][Full Text] [Related]
25. Factors Affecting Recurrence and Survival After Liver Transplantation for Hepatocellular Carcinoma.
Yilmaz C; Karaca CA; Iakobadze Z; Farajov R; Kilic K; Doganay L; Kilic M
Transplant Proc; 2018 Dec; 50(10):3571-3576. PubMed ID: 30577240
[TBL] [Abstract][Full Text] [Related]
26. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Bray F; Ferlay J; Soerjomataram I; Siegel RL; Torre LA; Jemal A
CA Cancer J Clin; 2018 Nov; 68(6):394-424. PubMed ID: 30207593
[TBL] [Abstract][Full Text] [Related]
27. More Than Just Wait Time? Regional Differences in Liver Transplant Outcomes for Hepatocellular Carcinoma.
Hogen R; Lo M; DiNorcia J; Ji L; Genyk Y; Sher L; Dhanireddy K
Transplantation; 2019 Apr; 103(4):747-754. PubMed ID: 29672442
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.
Marrero JA; Kulik LM; Sirlin CB; Zhu AX; Finn RS; Abecassis MM; Roberts LR; Heimbach JK
Hepatology; 2018 Aug; 68(2):723-750. PubMed ID: 29624699
[No Abstract] [Full Text] [Related]
29. Prediction of Therapeutic Response of Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization Based on Pretherapeutic Dynamic CT and Textural Findings.
Park HJ; Kim JH; Choi SY; Lee ES; Park SJ; Byun JY; Choi BI
AJR Am J Roentgenol; 2017 Oct; 209(4):W211-W220. PubMed ID: 28813195
[TBL] [Abstract][Full Text] [Related]
30. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.
Agopian VG; Harlander-Locke MP; Ruiz RM; Klintmalm GB; Senguttuvan S; Florman SS; Haydel B; Hoteit M; Levine MH; Lee DD; Taner CB; Verna EC; Halazun KJ; Abdelmessih R; Tevar AD; Humar A; Aucejo F; Chapman WC; Vachharajani N; Nguyen MH; Melcher ML; Nydam TL; Mobley C; Ghobrial RM; Amundsen B; Markmann JF; Langnas AN; Carney CA; Berumen J; Hemming AW; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Busuttil RW
Ann Surg; 2017 Sep; 266(3):525-535. PubMed ID: 28654545
[TBL] [Abstract][Full Text] [Related]
31. Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States.
Yang JD; Larson JJ; Watt KD; Allen AM; Wiesner RH; Gores GJ; Roberts LR; Heimbach JA; Leise MD
Clin Gastroenterol Hepatol; 2017 May; 15(5):767-775.e3. PubMed ID: 28013117
[TBL] [Abstract][Full Text] [Related]
32. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
Mehta N; Heimbach J; Harnois DM; Sapisochin G; Dodge JL; Lee D; Burns JM; Sanchez W; Greig PD; Grant DR; Roberts JP; Yao FY
JAMA Oncol; 2017 Apr; 3(4):493-500. PubMed ID: 27838698
[TBL] [Abstract][Full Text] [Related]
33. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation.
Lai Q; Avolio AW; Graziadei I; Otto G; Rossi M; Tisone G; Goffette P; Vogel W; Pitton MB; Lerut J;
Liver Transpl; 2013 Oct; 19(10):1108-18. PubMed ID: 23873764
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor cells measurements in hepatocellular carcinoma.
Chiappini F
Int J Hepatol; 2012; 2012():684802. PubMed ID: 22690340
[TBL] [Abstract][Full Text] [Related]
35. Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation.
Zen C; Zen Y; Mitry RR; Corbeil D; Karbanová J; O'Grady J; Karani J; Kane P; Heaton N; Portmann BC; Quaglia A
Liver Transpl; 2011 Aug; 17(8):943-54. PubMed ID: 21491582
[TBL] [Abstract][Full Text] [Related]
36. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
Lencioni R; Llovet JM
Semin Liver Dis; 2010 Feb; 30(1):52-60. PubMed ID: 20175033
[TBL] [Abstract][Full Text] [Related]
37. Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Post-transplant Clinical Outcome.
Adeniji N; Arjunan V; Prabhakar V; Tulu Z; Kambham N; Ahmed A; Kwo P; Dhanasekaran R
Clin Transplant; 2020 Dec; 34(12):e14128. PubMed ID: 33098134
[TBL] [Abstract][Full Text] [Related]
38. Bridging to liver transplantation in HCC patients.
Kollmann D; Selzner N; Selzner M
Langenbecks Arch Surg; 2017 Sep; 402(6):863-871. PubMed ID: 28755240
[TBL] [Abstract][Full Text] [Related]
39. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate.
Cescon M; Cucchetti A; Ravaioli M; Pinna AD
J Hepatol; 2013 Mar; 58(3):609-18. PubMed ID: 23041304
[TBL] [Abstract][Full Text] [Related]
40. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.
Pompili M; Francica G; Ponziani FR; Iezzi R; Avolio AW
World J Gastroenterol; 2013 Nov; 19(43):7515-30. PubMed ID: 24282343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
